Page 2 of 8, showing 50 records out of 362 total, starting on record 51, ending on 100
| Publication |
Category |
Year |
|
312. Labrie, F., Simard, J., Singh, S.M., Candas, B. (1997) Estimated potency of Casodex: A problematic design [Letter to the Editor re Schellhammer et al. 45: 745-52, 1995]. Urology, 50: 309-313. |
Prostate Cancer |
1997 |
|
311. Levesque, M.H., El-Alfy, M., Berger, L., Labrie, F., Labrie, C. (2007) Evaluation of AIbZIP and Cdc47 as Markers for Human Prostatic Diseases. Urology, 69: 196-201. |
Prostate Cancer |
2007 |
|
310. Luo, S., Martel, C., Leblanc, G., Candas, B., Singh, S.M., Labrie, C., Simard, J., Bélanger, A., Labrie, F. (1996) Relative potencies of flutamide and casodex: preclinical studies. Endocrine-Related Cancer, 3: 229-241. |
Prostate Cancer |
1996 |
|
309. Luu-The, V., Bélanger, A., Labrie, F. (2008) Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab, 22: 207-221. |
Prostate Cancer |
2008 |
|
308. Ma, C., Yoshioka, M., Boivin, A., Belleau, P., Gan, L., Takase, Y., Labrie, F., St-Amand, J. (2008) Erratum: Prostate specific genes and their regulation by dihydrotestosterone. Prostate, 68: 1372. |
Prostate Cancer |
2008 |
|
307. Ma, C., Yoshioka, M., Boivin, A., Belleau, P., Gan, L., Takase, Y., Labrie, F., St-Amand, J. (2008) Prostate specific genes and their regulation by dihydrotestosterone. Prostate, 68: 241-254. |
Prostate Cancer |
2008 |
|
306. Pelletier, G., Labrie, C., Labrie, F. (2000) Localization of oestrogen receptor alpha oestrogen receptor β and androgen receptors in the rat reproductive organs. J. Endocrinol., 165: 359-370. |
Prostate Cancer |
2000 |
|
305. Pelletier, G., Luu-The, V., El Alfy, M., Li, S., Labrie, F. (2001) Immunoelectron microscopic localization of 3β-hydroxysteroid dehydrogenase and type 5 17β-hydroxysteroid dehydrogenase in the human prostate and mammary gland. J. Mol. Endocrinol., 26: 11-19. |
Prostate Cancer |
2001 |
|
304. Perreira De Jésus, K., Côté, P.L., Cantin, L., Blanchet, J., Labrie, F., Breton, R. (2006) Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Science: a publication of the Protein Society, 15: 987-99. |
Prostate Cancer |
2006 |
|
303. Prostate Cancer Triallist’ Collaborative Group; (2000) Maximum androgen blockade in advanced prostate cancer: an overvierw of the randomised trials. Lancet, 355: 1491-1498. |
Prostate Cancer |
2000 |
|
302. Qiu, W., Zhou, M., Labrie, F., Lin, S.-X. (2004) Crystal structures of the multi-specific 17β-hydroxysteroid dehydrogenase type 5: Critical androgen regulation in human peripheral tissues. Mol Endocrinol, 18: 1798-1807. |
Prostate Cancer |
2004 |
|
301. Roach III, M.J., Thrasher, J.B., Blasko, J., Raben, D., Stone, N., Katz, A., Labrie, F. (2001) Prostatectomy, brachytherapy, intensity modulated radiotherapy, hormonal-radiotherapy, salvae cryosurgery and the role of combined hormonal blokade in the treatment of prostate cancer. Reviews in Urology, 3: S49-S58. |
Prostate Cancer |
2001 |
|
300. Roy, J., Breton, R., Martel, C., Labrie, F., Poirier, D. (2007) Chemical synthesis and biological activities of 16α-derivatives of 5α-androstane-3α, 17 β-diol as antiandrogens. Bioorg Med Chem, 15: 3003-3018. |
Prostate Cancer |
2007 |
|
299. Samson, M., Labrie, F., Zouboulis, C.C., Luu-The, V. (2010) Biosynthesis of dihydrotestosterone by a pathway that does not require testosterone as intermediate in the SZ95 sebaceous gland cell line. J Invest Derm. 130:602-604 |
Prostate Cancer |
2010 |
|
298. Simard, J., Dumont, M., Labuda, D., Sinnett, D., Meloche, C., El Alfy, M., Berger, L., Lees, E., Labrie, F., Tavtigian, S.V. (2003) Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocrine Related Cancer, 10: 225-259. |
Prostate Cancer |
2003 |
|
297. Simard, J., Dumont, M., Soucy, P., Labrie, F., Tavtigian, S.V. (2004) Prostate Cancer Susceptibility Genes, in: Labrie, F. et Koutsilieris, M., eds: Prostate Cancer: Understanding the pathophysiology and re-designing a therapeutic approach, Athens, Greece, Paschalidis Medical Publications, pp 1-38. |
Prostate Cancer |
2004 |
|
296. Simard, J., Singh, S.M., Labrie, F. (1997) Comparison of in vitro effects of the pure antiandrogens OH-Flutamide, Casodex and Nilutamide on androgen-sensitive parameters. Urology, 49: 580-589. |
Prostate Cancer |
1997 |
|
295. Singh, R., Eeles, R.A., Durocher, F., Simard, J., Edwards, S., Badzioch, M., Kote-Jarai, Z., Teare, D., Fortd, D., Dearnaley, D., Ardern-Jones, A., Murkin, A., Dowe, A., Shearer, R., Kelly, J., Labrie, F., Easton, D., Narod, S.A., Tonin, P.N., Foulkes, W.D. (2000) High risk genes predisposing to prostate cancer development-do they exist? Prostate Cancer Prostatic Dis., 3: 241-247. |
Prostate Cancer |
2000 |
|
294. Suzuki, K., Nishiyama, T., Hara, N., Yamana, K., Takahashi, K., Labrie, F. (2007) Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer. Prostate Cancer Prostatic Dis., 10: 301-6. |
Prostate Cancer |
2007 |
|
293. Swanson, C., Mellström, D., Lorentzon, M., Vanderput, L., Jakobsson, J., Rane, A., Karlsson, M., Ljunggren, O., Smith, U., Eriksson, A.E., Bélanger, A., Labrie, F., Ohlsson, C. (2007) The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men. J Clin Endocrinol Metab, 92: 4878-4882. |
Prostate Cancer |
2007 |
|
292. Têtu, B., Van der kwast, T., Fradet, Y., Candas, B., Gomez, J.L., Cusan, L., Labrie, F. (1998) Morphologic effects of neoadjuvant hormone therapy on prostate cancer. Mol. Urol., 2: 103-107. |
Prostate Cancer |
1998 |
|
291. Takase, Y., Lévesque, M.H., Luu-The, V., El-Alfy, M., Labrie, F., Pelletier, G. (2006) Expression of enzymes involved in estrogen metabolism in human prostate. J.Histochem Cytochem., 54: 911-21. |
Prostate Cancer |
2006 |
|
290. Takase, Y., Luu-The, V., Poisson-Paré, D., Labrie, F., Pelletier, G. (2007) Expression of sulfotransferase 1E1 in human prostate as studied by in situ hybridization and immunocytochemistry. Prostate, 67: 405-409. |
Prostate Cancer |
2007 |
|
289. Tavtigian, S.V., Simard, J., Teng, D.H.F., Abtin, V., Baumgard, M., Beck, A., Camp, N.J., Carillo, A.R., Chen, Y., Dayananth, P., Desrochers, M., Dumont, M., Farnham, J.M., Frank, D., Frye, C., Ghaffari, S., Gupte, J.S., Hu, R., Iliev, D., Janecki, T., Kort, E.N., Laity, K.E., Leavitt, A., Leblanc, G., McArthur-Morrison, J., Pederson, A., Penn, B., Peterson, K.T., Reid, J.E., Richards, S., Schroeder, M., Smith, R., Snyder, S.C., Swedlund, B., Swensen, J., Thomas, A., Tranchant, M., Woodland, A.-M., Labrie, F., Skolnick, M.H., Neuhausen, S., Rommens, J., Cannon-Albright, L.A. (2001) A candidate prostate cancer susceptibility gene at chromosome 17p. Nat. Genet., 27: 172-180. |
Prostate Cancer |
2001 |
|
288. Tenta, R., Katopodis, H., Chatzïioannou, A., Pilalis, E., Calvo, E., Luu-The, V., Labrie, F., Kolisis, F., Koutsilieris, M. (2007) Microarray analysis of survival pathways in human PC-3 prostate cancer cells. Cancer Genomics Proteomics, 4: 309-18. |
Prostate Cancer |
2007 |
|
287. van der Kwast, T.H., Tetu, B., Fradet, Y., Dupont, A., Gomez, J., Cusan, L., Diamond, P., Labrie, F. (1996) Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy. Prostate, 28: 227-231. |
Prostate Cancer |
1996 |
|
286. Vandenput, L., Labrie, F., Mellström, D., Swanson, C., Knutsson, T., Peeker, R., Ljunggren, O., Orwoll, E., Eriksson, A.L., Johnell, O., Damber, J.E., Ohlsson, C. (2007) Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. J. of Bone and Mineral Research: The Official Journal of the American Soc. for Bone and Mineral Research, 22: 220-7. |
Prostate Cancer |
2007 |
|
285. Xu, J., The International Consortium for Prostate Cancer Genetics. (2000) Combined Analysis of Hereditary Prostate Cancer Linkage to 1q24-25: Results from 772 Hereditary Prostate Cancer Families from the International Consortium for Prostate Cancer Genetics. Am J Hum Genet., 66: 945-57. |
Prostate Cancer |
2000 |
|
284. Asselin, J., Labrie, F., Gourdeau, Y., Bonne, C., Raynaud, J.P. (1976) Binding of [3H]methyltrienolone (Rl88l) in rat prostate and human benign prostatic hypertrophy (BPH). Steroids, 28: 449-459. |
Prostate Cancer |
1976 |
|
283. Auclair, C., Cusan, L., Kledzik, G.S., Ferland, L., Kelly, P.A., Labrie, F. (1978) Inhibition de fonctions gonadiques par la LHRH et ses agonistes chez le rat mâle et femelle. Union Med. Can., 107: 356-364. |
Prostate Cancer |
1978 |
|
282. Auclair, C., Ferland, L., Cusan, L., Kelly, P.A., Labrie, F., Azadian-Boulanger, G., Raynaud, J.P. (1978) Effet inhibiteur de la LHRH sur les récepteurs de la LH dans le testicule chez le rat. C.R. Acad. Sci. Hebd. Seances Acad. Sci. D, 286: 1305-1307. |
Prostate Cancer |
1978 |
|
281. Auclair, C., Kelly, P.A., Coy, D.H., Schally, A.V., Labrie, F. (1977) Potent inhibitory activity of [D-Leu6, des-Gly-NH2 10]ethylamide on LH/hCG and PRL testicular receptor levels in the rat. Endocrinology, 101: 1890-1893. |
Prostate Cancer |
1977 |
|
280. Auclair, C., Kelly, P.A., Labrie, F., Coy, D.H., Schally, A.V. (1977) Inhibition of testicular LH/hCG receptor level by treatment with a potent LHRH agonist or hCG. Biochem. Biophys. Res. Commun., 76: 855-862. |
Prostate Cancer |
1977 |
|
279. Azzi, A., Rehse, P.H., Zhu, D.-W., Campbell, R.L., Labrie, F., Lin, S.-X. (1996) Crystal structure of human estrogenic 17?-hydroxysteroid dehydrogenase complexed with 17?-estradiol. Nat. Struct. Biol., 3: 665-668. |
Prostate Cancer |
1996 |
|
278. Bégin, D., Luthy, I.A., Labrie, F. (1988) Adrenal precursor C19 steroids are potent stimulators of growth of androgen-sensitive mouse mammary carcinoma Shionogi cells in vitro. Mol. Cell. Endocrinol., 58: 213-219. |
Prostate Cancer |
1988 |
|
277. Bélanger, A., Auclair, C., Ferland, L., Caron, S., Labrie, F. (1980) Time-course of the effect of treatment with a potent LHRH agonist on testicular steroidogenesis and gonadotropin receptor levels in the adult rat. J. Steroid Biochem., 13: 191-196. |
Prostate Cancer |
1980 |
|
276. Bélanger, A., Auclair, C., Séguin, C., Caron, S., Labrie, F. (1981) Prolactin stimulation of testicular steroid biosynthesis in the male rat. J. Androl., 2: 80-86. |
Prostate Cancer |
1981 |
|
275. Bélanger, A., Auclair, C., Séguin, C., Kelly, P.A., Labrie, F. (1979) Down-regulation of testicular androgen biosynthesis and LH receptor levels by an LHRH agonist: role of prolactin. Mol. Cell. Endocrinol., 13: 47-53. |
Prostate Cancer |
1979 |
|
274. Bélanger, A., Brochu, M., Lacoste, D., Noel, C., Labrie, F., Dupont, A., Cusan, L., Caron, S., Couture, J. (1991) Steroid glucuronides: human circulatory levels and formation by LNCaP cells. J. Steroid Biochem. Mol. Biol., 40: 593-598. |
Prostate Cancer |
1991 |
|
273. Bélanger, A., Candas, B., Dupont, A., Cusan, L., Diamond, P., Gomez, J.L., Labrie, F. (1994) Changes in serum concentration of conjugated and unconjugated steroids in 40- to 80-year old men. J. Clin. Endocrinol. Metab., 79: 1086-1090. |
Prostate Cancer |
1994 |
|
272. Bélanger, A., Caron, S., Cusan, L., Séguin, C., Auclair, C., Labrie, F. (1981) Inhibition of testicular androgen biosynthesis by treatment with LHRH agonists, in: McKerns, K.W., ed. Reproductive Processes and Contraception. International Society for Biochemical Endocrinology, New York, Plenum Press, pp 471-491. |
Prostate Cancer |
1981 |
|
271. Bélanger, A., Cusan, L., Auclair, C., Séguin, C., Caron, S., Labrie, F. (1980) Effect of an LHRH agonist and hCG on testicular steroidogenesis in the adult rat. Biol. Reprod., 22: 1094-1101. |
Prostate Cancer |
1980 |
|
270. Bélanger, A., Cusan, L., Séguin, C., Caron, S., Labrie, F. (1980) Inhibition de la stéroïdogénèse testiculaire chez le rat par traitement avec un agoniste de la LHRH. Union Med. Can., 109: 489-494. |
Prostate Cancer |
1980 |
|
269. Bélanger, A., Dupont, A., Labrie, F. (1984) Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer. J. Clin. Endocrinol. Metab., 59: 422-426. |
Prostate Cancer |
1984 |
|
268. Bélanger, A., Giasson, M., Cliche, J., Dupont, A., Labrie, F. (1988) Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide. Prostate, 12: 79-84. |
Prostate Cancer |
1988 |
|
267. Belanger, A., Labrie, F., Dupont, A., Brochu, M., Cusan, L. (1988) Endocrine effects of combined treatment with an LHRH agonist in association with Flutamide in metastatic prostatic carcinoma. Clin. Invest. Med., 11: 321-326. |
Prostate Cancer |
1988 |
|
266. Belanger, A., Labrie, F., Lemay, A., Caron, S., Raynaud, J.P. (1980) Inhibitory effects of a single intranasal administration of [D-Ser(TBU)6, des-Gly -NH210]LHRH ethylamide, a potent LHRH agonist, on serum steroid levels in normal adult men. J. Steroid Biochem., 13: 123-126. |
Prostate Cancer |
1980 |
|
265. Bélanger, A., Labrie, F., Séguin, C., Cusan, L., Carmichael, R., Caron, S. (1983) Inhibition of testicular delta 4-androgen secretion in the rat by treatment with luteinizing hormone-releasing hormone, in: Negro-Vilar, A., ed. Male Reproduction and Fertility, New York, Raven Press, pp 127-139. |
Prostate Cancer |
1983 |
|
264. Bélanger, A., Rong, P.M., Liu, S., Lavoie, L., Labrie, F. (1993) Characterization and measurement of prostate-specific antigen using monoclonal antibodies. Clin. Invest. Med., 16: 409-415. |
Prostate Cancer |
1993 |
|
263. Bélanger, A., Tremblay, Y., Lacoste, D., Giasson, M., Dupont, A., Labrie, F. (1984) The dog, a good model for the study of LHRH agonists as blockers of androgen secretion and potential contraceptives, in: Labrie, F., Bélanger, A. et Dupont, A., eds: Proceedings of the International Symposium on LHRH and its Analogues: Basic and Clinical Aspects, New York, Excerpta Medica, pp 141-155. |
Prostate Cancer |
1984 |